Aquatic Capital Management LLC Makes New Investment in Galapagos NV (NASDAQ:GLPG)

Aquatic Capital Management LLC acquired a new position in shares of Galapagos NV (NASDAQ:GLPG - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 26,418 shares of the biotechnology company's stock, valued at approximately $726,000.

A number of other institutional investors and hedge funds have also modified their holdings of the company. R Squared Ltd bought a new position in shares of Galapagos in the fourth quarter worth about $26,000. GAMMA Investing LLC increased its stake in shares of Galapagos by 77.4% in the 4th quarter. GAMMA Investing LLC now owns 2,233 shares of the biotechnology company's stock valued at $61,000 after buying an additional 974 shares during the period. QRG Capital Management Inc. boosted its holdings in Galapagos by 21.7% in the fourth quarter. QRG Capital Management Inc. now owns 10,455 shares of the biotechnology company's stock valued at $288,000 after acquiring an additional 1,866 shares during the last quarter. XTX Topco Ltd boosted its stake in shares of Galapagos by 137.8% in the 4th quarter. XTX Topco Ltd now owns 19,833 shares of the biotechnology company's stock valued at $545,000 after purchasing an additional 11,492 shares during the last quarter. Finally, American Century Companies Inc. boosted its holdings in Galapagos by 5.9% during the fourth quarter. American Century Companies Inc. now owns 25,852 shares of the biotechnology company's stock worth $711,000 after buying an additional 1,431 shares during the last quarter. 32.46% of the stock is currently owned by institutional investors.

Galapagos Trading Down 1.0 %

NASDAQ:GLPG traded down $0.25 during midday trading on Wednesday, reaching $26.02. 120,106 shares of the stock traded hands, compared to its average volume of 213,812. Galapagos NV has a 12 month low of $22.36 and a 12 month high of $31.23. The company has a fifty day moving average of $25.43 and a 200 day moving average of $26.05.

Galapagos (NASDAQ:GLPG - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The biotechnology company reported ($2.47) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by ($2.24). The business had revenue of $97.33 million for the quarter, compared to analyst estimates of $72.22 million. On average, research analysts predict that Galapagos NV will post -1.6 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on GLPG. Barclays restated an "underweight" rating on shares of Galapagos in a research report on Thursday, January 23rd. TD Cowen lowered shares of Galapagos from a "strong-buy" rating to a "strong sell" rating in a research note on Thursday, January 9th. Morgan Stanley lowered shares of Galapagos from an "equal weight" rating to an "underweight" rating and dropped their price objective for the company from $31.00 to $22.00 in a research note on Friday, February 14th. Finally, StockNews.com lowered shares of Galapagos from a "hold" rating to a "sell" rating in a report on Friday, April 25th. Five analysts have rated the stock with a sell rating and four have given a hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Reduce" and a consensus target price of $25.33.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.